Asako Uchiyama, PhD, Board Director and Chief Development Officer of Celaid Therapeutics Inc., will speak at the AABB Annual Meeting and Cord Blood Connect, taking place October 17–19, 2026, in Atlanta, Georgia.
Asako will participate in the session titled “Cord Blood Derived Therapies from Pre-Clinical to Commercial: Real World Examples Coming Your Way” on Monday, October 19, from 8:15 to 9:15 AM.
During the session, Asako will present Celaid’s proprietary hematopoietic stem cell (HSC) expansion technology and its lead product candidate, CLD-001, an allogeneic HSC therapy currently under development for clinical applications in the United States.
AABB Annual Meeting and Cord Blood Connect
